Quantcast

Latest Cordis Stories

2010-05-11 06:45:00

Peripheral Vascular Device Market to Almost Double by 2016 VANCOUVER, May 11 /PRNewswire-FirstCall/ - According to a new report by iData Research (www.idataresearch.net), the leading authority in medical device and pharmaceutical market research, the U.S. peripheral vascular device market is worth $2.8 billion with expected growth to over $5.3 billion by 2016. Increased detection and treatment of abdominal aortic aneurysms (AAAs) and peripheral arterial disease (PAD) are the main drivers of...

2010-04-06 11:19:00

WATERLOO, Belgium, April 6, 2010 /PRNewswire/ -- Cordis Corporation announced that Christian M. Spaulding, M.D., Ph.D., FESC, FACC, has been named as Worldwide Vice President of Medical Affairs. In this role, he will be a key leader of the company's medical team, responsible for leading the company's global clinical strategy. Dr. Spaulding will assume the role on June 1, and will be based in Paris. "We are very pleased that a cardiologist of Dr. Spaulding's stature is joining...

2010-03-17 14:08:00

WATERLOO, Belgium, March 17, 2010 /PRNewswire/ -- - SORT OUT III Data Presented at American College of Cardiology Meeting in Atlanta and Published in the Lancet Investigators reported the long-term follow-up of the largest randomized comparison between the CYPHER(R) Sirolimus-eluting Coronary Stent and Medtronic's Endeavor(R) Stent highlighting significant and sustained clinical differences. These important findings were presented at the American College of Cardiology annual...

2010-03-11 04:14:00

WATERLOO, Belgium, March 11, 2010 /PRNewswire/ -- - PRESILLION(TM) PLUS CoCr Coronary Stent Offers New Levels of Delivery, Support and Restoration for Arteriosclerotic Arteries Cordis Corporation today announced the European launch of its next generation of bare metal stent system - PRESILLION(TM) PLUS. The new stent system, which improves upon the ground-breaking PRESILLION(TM), features important technological advances designed to gain easier access to distal lesions and help...

2010-03-02 13:03:00

NEW BRUNSWICK, N.J., March 2 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 30th Annual Cowen and Company Health Care Conference on Tuesday, March 9th at the Boston Marriott Copley Place Hotel in Boston, MA. Seth Fischer, Company Group Chairman, Worldwide Franchise Chairman, Cordis, will represent the Company in a session scheduled at 11:05 a.m. (Eastern Time). The webcast will be available to investors and other interested parties by accessing the...

2010-02-01 07:00:00

BRIDGEWATER, N.J., Feb. 1 /PRNewswire/ -- Cordis Corporation, a Johnson & Johnson company, announced today that it has reached an agreement with Boston Scientific resolving two Delaware litigations related to Cordis's Palmaz and Gray patents and Boston Scientific's Jang patents. Under the terms of the agreement, Cordis will receive $1.725 billion from Boston Scientific and Johnson & Johnson expects to record the majority of this payment as a special item in the first quarter of...

2009-12-14 07:07:00

WALTHAM, Mass., Dec. 14 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, Japan's complex regulatory environment and lengthy device approval process has created a significant lag in peripheral vascular stenting device availability in the country compared to other developed nations. MRG's new Japanese Markets for Peripheral Vascular Devices 2010 report finds, however, that recent indication-specific device...

2009-12-09 12:13:00

HONG KONG, Dec. 9 /PRNewswire/ -- OrbusNeich today announced that Al Novak has been elected chairman of the board. Novak, 61 years old, will continue to serve as president and chief executive officer of OrbusNeich, the role that he has held since 2008. He brings over 27 years of leadership experience in the medical technology industry to the position having served as chief executive officer of Novoste Corporation and Biosense, Inc. and in marketing and financial positions with Cordis...

2009-11-18 10:50:00

NEW YORK, Nov. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Drug-Eluting Stents - Global Market Opportunities http://www.reportlinker.com/p0164240/Drug-Eluting-Stents---Global-Market-Opportunities.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire Increasing acceptance of stents as viable treatment option, expanding patient population seeking drug-eluting stents, and higher reimbursement coverage...

2009-05-28 09:21:00

Positive clinical data, competitor focus, and new drug-eluting technologies to drive lower extremity procedures in Europe, according to Millennium Research Group WALTHAM, Mass., May 28 /PRNewswire/ -- According to Millennium Research Group's (MRG's) European Markets for Peripheral Vascular (PV) Devices 2009 report, rapid growth in the number of endovascular procedures that treat lower extremity peripheral artery disease in Europe is being fueled by positive clinical trial results, increased...


Word of the Day
callithump
  • A somewhat riotous parade, accompanied with the blowing of tin horns, and other discordant noises; also, a burlesque serenade; a charivari.
'Callithump' is a back-formation of 'callithumpian,' a 'fanciful formation' according to the Oxford English Dictionary. However, the English Dialect Dictionary, says 'Gallithumpians' is a Dorset and Devon word from the 1790s that refers to 'a society of radical social reformers' or 'noisy disturbers of elections and meetings.'
Related